Nabsys Announces New OhmX Platform Installations Under Hitachi High-Tech America's RAMP UP Program with Leading Cytogeneticist to Advance Applications in Hematologic Malignancies
Nabsys 2.0, LLC has announced a collaboration with Hitachi High-Tech America, Inc. to advance research in hematological malignancies through the OhmX ™ Rapid Application to Market Penetration User Partnership (RAMP UP) program. Brynn Levy, M.Sc.(Med)., Ph.D., FACMG, a Professor at Columbia University Vagelos College of Physicians and Surgeons, has joined the program to enhance research in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using electronic genome mapping technology.
The RAMP UP program aims to place the Nabsys OhmX Platform in leading research laboratories, facilitating translational studies and generating data necessary for the acceleration of new electronic genome mapping (EGM) applications. Several OhmX Platforms have been installed in Dr. Levy's laboratory as part of a sponsored research agreement, designed to address gaps in leukemia research and cytogenetic workflows.
Current cytogenetic methods often analyze only a limited subset of genetic loci or provide low-resolution structural analyses, making it complex to apply genome-wide technologies to specific studies. The collaboration seeks to bridge this gap by enabling high-resolution structural investigations of known leukemia driver loci within established workflows.
The OhmX Platform utilizes electronic detection through a nanochannel-based architecture to analyze ultra-long DNA molecules. This method supports detailed characterization of structural variants while integrating broader copy number context, which is crucial in diseases like AML and MDS that are influenced by structural variations. The platform aims to improve the accessibility of structural variation and copy number variation analysis, potentially benefiting researchers with enhanced genomic data.
Dr. Levy emphasized the importance of structural variation in diseases like AML and MDS, stating that next-generation tools capable of providing high-resolution insights into relevant genomic regions could enable new types of translational research. Nabsys plans to focus on targeted structural variant analysis in these cancers, with opportunities to expand into broader applications over time.